On March 18, 2026, the University of Calgary is set to advance its research into the therapeutic effects of THC capsules. This clinical trial, which is being led by Dr. Leah Mayo, involves 24 healthy adult participants.
Participants in the study are taking capsules that contain varying doses of THC: 6, 9, or 15 milligrams, along with a placebo group. The primary goal of this research is to map the therapeutic window for oral THC, specifically focusing on its potential to reduce anxiety and stress.
Avicanna Inc. is supplying the THC capsules for this trial, utilizing their proprietary Self-Emulsifying Drug Delivery System (SEDDs) technology. This innovative approach aims to enhance the bioavailability of THC, which could lead to more effective treatment options for anxiety-related disorders.
Dr. Leah Mayo commented on the study, stating, “With some doses people feel a reduction in their anxiety but at higher doses they can feel an increase in anxiety.” This highlights the complexity of THC’s effects and the importance of determining the right dosage for therapeutic use.
Avicanna has been making significant strides in the cannabis research field, generating approximately C$18.9 million in revenue over the nine months ending September 30, 2025, with a gross margin of 52 percent. The company has successfully eliminated its debt and is progressing towards achieving positive adjusted EBITDA.
In addition to this trial, the University of Calgary is actively participating in national teams that are studying the effects of cannabis on brain health and cardiovascular risks. This collaboration underscores the institution’s commitment to advancing research in the evolving field of cannabinoid therapy.
The outcomes of this trial could have significant implications for the understanding of THC’s role in managing anxiety and stress, potentially influencing future therapeutic practices. As research continues, the findings may contribute to a broader understanding of cannabis’s benefits and risks.
As the trial progresses, stakeholders are keenly observing its developments, given the increasing interest in cannabis-based treatments for mental health issues. The results could pave the way for new therapeutic approaches and further research in this area.
Details remain unconfirmed regarding the specific timeline for the trial’s completion and subsequent analysis of results, but the implications of this research are already being felt across the cannabis and healthcare sectors.
